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Abstract
Bleeding during liver surgery and liver transplantation 
(LT) can be caused by coagulation disorders, portal 
vein hypertension, and adhesions from previous surgi-
cal procedures. We describe here how we controlled 
life-threatening bleeding from a portal vein anastomosis 
during a third cadaveric LT, by using a carrier-bound 
sealant (TachoSil). This technique proved effective to 
control severe anastomotic portal bleeding in this situ-
ation. It represents a helpful option in the fi eld of LT, 
when vascular bleeding cannot be stopped by other 
methods.
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Introduction
Hemostasis can be challenging during liver transplanta-
tion (LT) in patients with underlying coagulation 
disorders.1 Several new products consisting of human 
coagulation factors are now available to assist in the 
control of bleeding and to attain hemostasis during 
surgery.2 We report a case of life-threatening bleeding 
from a portal vein anastomosis during a third cadaveric 
LT, aggravated by portal hypertension and a very 
fragile portal vein. As the bleeding was not able to be 
stopped by suturing, we used a hemostatic tissue sealant 
(TachoSil; Nycomed, Zurich, Switzerland), which 
proved extremely effi cient.
Technique
A 32-year-old woman underwent a full cadaveric LT 
for viral hepatitis C (HCV)-related cirrhosis. A recur-
rence of the HCV led to cirrhosis of the graft, and a 
retransplantation was done 1 year later. Despite treat-
ment with interferon and ribavirin, HCV recurred 
2 years later, necessitating a third LT for cirrhosis. 
Severe portal hypertension and the adhesions left by 
the previous surgery made the operation challenging. 
The portal vein was kinked and dilated to more than 
3 cm in diameter, with an extremely fragile and thin 
wall. The kinking made resection of a segment of the 
vein necessary. The subsequent portal anastomosis was 
made technically diffi cult by the recipient’s short and 
fragile portal vein stump. Thus, we performed the anas-
tomosis with a 6-0 polypropylene running suture with 
a 1-cm growth factor. After declamping the portal vein, 
the suture line and holes made by the stitches started 
bleeding profusely (Fig. 1). Attempts to stop the hem-
orrhage with stitches exacerbated the bleeding as the 
thread cut through the fragile portal wall. A new 
anastomosis or an interposed vascular graft would have 
been diffi cult under these conditions. As a feasible 
option at this critical stage, we decided to place a patch 
coated with human coagulation factors (TachoSil) 
around the suture line. First, we cut a single patch 
of TachoSil, moistened in saline solution, into the 
appropriate shape (approximately 1.5 cm wide) and 
placed it around the vein. The active yellow side of 
the hemostatic device was in contact with the vessel 
wall, covering the whole anastomotic suture line. Slight 
manual pressure was applied using a small wet sponge 
for 5 min (Fig. 2). Afterwards, the clots around the 
hepatic pedicle were removed carefully, keeping the 
patch in place without peeling the vein. The bleeding 
was thereby controlled and the hemorrhage stopped 
(Fig. 3). The subsequent surgical course was 
uneventful.
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Discussion
To our knowledge, this represents the fi rst report 
describing the successful control of critical bleeding of 
a portal vein anastomosis, using TachoSil, a modern 
biological hemostatic and tissue sealant consisting of an 
equine collagen fl eece patch containing fi brinogen and 
human thrombin without aprotinin. It delivers fi brino-
gen and thrombin to the site of bleeding, forming a 
fi brin network, which glues the collagen sponge to the 
wound surface.3 The major concern relates to the risk 
of HIV or hepatitis transmission associated with the use 
of human coagulation proteins contained in this sealant. 
However, no such infections have been reported in 20 
years of its use worldwide.4
This sealant is a further development of TachoComb 
and TachoComb H and is applied in several areas 
of surgery for the control or prevention of bleeding. 
TachoSil was used initially in thoracic surgery, where it 
not only controls bleeding, but also prevents pleural 
adhesions (animal study5) and air leaks (randomized 
control trial in humans6). In general surgery, TachoSil 
has been used mainly to control bleeding of cut surfaces 
of solid organs. In a randomized controlled trial by 
Frilling et al., TachoSil was superior to the argon beamer 
in obtaining fast and effective intraoperative hemostasis 
of the liver surface after liver surgery.7 The safety and 
effectiveness of fi brin sealants has proven effective in 
Fig. 1. Massive bleeding in the area of the portal anastomosis 
after declamping
Fig. 2. Control of the bleeding by a TachoSil patch around 
the portal vein
Fig. 3. The TachoSil patch in place around the portal vein
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peripheral vascular surgery, particularly for preventing 
suture hole bleeding of grafts.3,8 In our patient’s third 
retransplant, the unexpected fragility and bleeding of 
the portal vein was life-threatening and could not have 
been controlled by additional surgical stitches. A reanas-
tomosis or an interposed vascular graft would have been 
very risky because of the fragility of the vein. The effec-
tiveness of TachoSil in this challenging, briefl y uncon-
trolled bleeding from the venous low pressure system 
was remarkable. Apart from the effi cacy of the hemo-
static product itself, the role of the surgeon in applying 
a slight fi nger pressure to the area of the leak for several 
minutes was crucial. It is important to note that once 
the patch is in place, it should not be replaced or 
removed. In conclusion, surgical coated patches such as 
TachoSil are useful not only for controlling the bleeding 
of solids organs in the abdominal surgery, but also for 
venous vascular bleeding, particularly in the fi eld of 
abdominal organ transplantation.
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